ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 437

Anti-Citrullinated Heat Shock Protein 90 Antibodies Identified in Bronchoalveolar Lavage Fluid Are a Marker of Lung-Specific Immune Responses

Lisa Harlow1, Bernadette Gochuico2, Ivan Rosas3, Tracy Doyle4, Juan Osorio4, Timothy Travers5, Carlos Camacho6, Chester V. Oddis7 and Dana P. Ascherman8, 1Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, 2Medical Genetics Branch, National Institutes of Health, Bethesda, MD, 3Medicine/Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 4Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 5Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, 6Compuational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, 7Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Anti-citrullinated protein/peptide antibodies (ACPA) and rheumatoid arthritis (RA), Lung Disease

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose .  Previous work has demonstrated an association between serum anti-citrullinated HSP90 antibodies and rheumatoid arthritis-associated interstitial lung disease (RA-ILD).  To further investigate this potential pathogenic relationship, we assessed anti-citrullinated HSP90 antibody profiles in bronchoalveolar lavage fluid (BALF) isolated from RA patients with and without ILD.

Methods .  BALF and corresponding serum samples were collected from a well-defined cohort of RA patients with various stages of ILD.  Specimens obtained from these subjects were then subjected to enzyme-linked immunosorbent assays (ELISAs) using recombinant HSP90 isoforms and derivative peptides as substrate antigens.  While comparison of resulting BALF-associated antibody profiles to those identified in healthy controls and patients with idiopathic pulmonary fibrosis (IPF) permitted assessment of disease specificity, evaluation of matching serum specimens provided insight regarding relative antibody production in lung and extra-pulmonary tissue compartments.

Results .  9/21 RA-derived BALF specimens demonstrated either IgG or IgA antibodies targeting citrullinated HSP90 proteins/peptides, highlighting disease specific immune responses (with a predilection for RA-ILD) that did not occur in IPF patients (0/5) or healthy control subjects (0/5).  Discordance between these antibody responses and BALF anti-CCP2 reactivity (IgG, IgA) provided clear evidence of antigen specificity (as only 3/21 BALF samples possessed antibodies recognizing both CCP2 and citrullinated HSP90 derivatives).  Furthermore, comparison of antibody profiles between BALF and matching serum specimens revealed several different recognition patterns favoring predominant production of anti-citrullinated HSP90 antibodies within the lung microenvironment.

Conclusion .  IgG and IgA anti-citrullinated HSP90 antibodies occur preferentially in BALF derived from patients with RA-ILD, supporting the connection between this antibody specificity and parenchymal lung disease.  Moreover, qualitative as well as quantitative differences in anti-citrullinated HSP90 profiles between BALF and serum indicate that the lung plays a direct role in shaping the immune repertoire of RA/RA-ILD.


Disclosure:

L. Harlow,
None;

B. Gochuico,
None;

I. Rosas,
None;

T. Doyle,
None;

J. Osorio,
None;

T. Travers,
None;

C. Camacho,
None;

C. V. Oddis,
None;

D. P. Ascherman,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-citrullinated-heat-shock-protein-90-antibodies-identified-in-bronchoalveolar-lavage-fluid-are-a-marker-of-lung-specific-immune-responses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology